ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, molecular methods that can be able to early detect BCR-ABL1 kinase domain mutations are very important for monitoring of CML patients after treatment with tyrosine kinase inhibitors (TKIs).